Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Provided By GlobeNewswire
Last update: May 13, 2025
64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL
Read more at globenewswire.comNASDAQ:ARTV (10/15/2025, 3:04:06 PM)
2.99
+0.12 (+4.18%)
Find more stocks in the Stock Screener
